Nevirapine

🧮 Dose calculator

HIV-1 infection (treatment) · Regimen source: FDA Nevirapine · 2.1

• • The 14-day lead-in must be followed (fewer rashes). Do not escalate with rash during lead-in; do not extend beyond 28 days. Interruption >7 days: restart lead-in. With other antiretrovirals. FDA Nevirapine · 2.4FDA Nevirapine · 2.1

Enter age (weight is optional for this regimen).

👥 Special populations

• 🤰 PregnancyUse with caution

  Label: Antiretroviral Pregnancy Registry data show no difference from the background birth-defect rate. FDA Nevirapine · 8.1

  “Available data from the APR show no difference in the risk of overall major birth defects for nevirapine compared with the background rate for major birth defects of 2.7% in the U.S. reference population of the Metropolitan Atlanta Congenital Defects Program (MACDP).”

• 🤱 BreastfeedingDangerous / avoid

  Label: breastfeeding not recommended, or choose between the drug and breastfeeding. FDA Nevirapine · 8.2

  “… 2) developing viral resistance (in HIV-positive infants), and (3) serious adverse reactions in nursing infants, mothers should not breastfeed if they are receiving nevirapine.”

• 👶 ChildrenUse with caution

  The label has conditions, age limits or notes for children; the label sentence is quoted below. FDA Nevirapine · 8.4

  “The safety, pharmacokinetic profile, and virologic and immunologic responses of nevirapine have been evaluated in HIV-1 infected pediatric subjects aged 3 months to 18 years [see Adverse Reactions (6.1) and Clinical Studies (14.2) ].”

• 👴 Older adultsUse with caution

  Label: use with caution in older adults, usually starting at the low end of the dose range. FDA Nevirapine · 8.5

  “In general, dose selection for an elderly patient should be cautious, reflecting the greater frequency of decreased hepatic, renal or cardiac function, and of concomitant disease or other drug therapy.”

• ⚥ Females & males of reproductive potentialUse with caution

  Label has advice on pregnancy testing, contraception or fertility for females and males. FDA Nevirapine · 8.3

  “Infertility Limited human data are insufficient to determine the risk of infertility in humans.”